LaNova Medicines, privately held biotech company headquartered in Shanghai, and LegoChem Biosciences, a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and the company’s patented ADC technology platform* ConjuAll™, have signed a collaborative research agreement to evaluate a novel antibody-drug conjugate (ADC) candidate for an undisclosed target expressed in solid tumors.[1]

The companies said the collaboration will focus on the development of a potential first-in-class ADC using antibodies discovered by LaNova Medicines.

“LaNova Medicines is excited to collaborate with LegoChem Biosciences, a leading global biotech with a proven track record in ADC development. Our considerable experience in antibody discovery, combined with LCB’s proprietary ADC technology platform, offers the potential to create more breakthrough medicines for patients worldwide.” noted Crystal Qin, Ph. D.,Founder, Chairman, and CEO of LaNova Medicines.

LaNova Medicines focuses on discovering novel biologic drugs in the fields of ADC and Immuno-oncology, with a dedication to providing innovative therapies that have the potential to be best-in-class or first-in-class and address significant unmet medical needs.

Advertisement #3 

LaNova Medicines’ expertise lies in the discovery and development of innovative biologic drugs. The company’s robust portfolio of biologic drug candidates is made possible by an industry-leading R&D engine comprising of three distinct platforms: a proprietary antibody platform capable of consistent production of antibodies against a variety of targets such as multi-transmembrane proteins and GPCRs, a clinical stage next-generation ADC platform that harnesses proprietary payload and linker technologies to construct highly differentiated ADCs, and a modular 4-1BB based immune-cell-engager (ICE) platform that enables efficient creation of therapeutic bispecific antibody against different tumor-associated antigens (TAAs).

The company’s present pipeline consists of more than 10 innovative drug candidates. The company’s leading clinical-stage programs include LM-302, a differentiate anti-Claudin 18.2 ADC licensed to Turning Point Therapeutics (now part of Bristol Myers Squibb) in 2022 for a total deal value of over 1 billion USD, LM-108, a potential best-in-class CCR8-targeting monoclonal antibody designed to address the unmet needs in PD-1 resistant cancer patients, and LM-101, an anti-SIRPα monoclonal antibody with strong potential to synergize with various anti-cancer agents such as anti-PD1 and ADC, all of which are currently being studied in Phase 1/2 studies.


[1] Hofland, P. LegoChem Biosciences Receives US Patent for Proprietary ConjuAll ADC Platform Technology. April 17, 2017, Online. last accesses on April 26, 2023.

Featured image by National Cancer Institute on Unsplash. Used with permission.

Advertisement #4